Gilead's new deal scout faces tough task as investors clamor for M&A

milligan
Speaking to analysts and investors on Tuesday, Gilead CEO John Milligan said that the drugmaker is looking at bulking up in oncology.

Armed with a revamped deal-scouting team, Gilead is eyeing oncology—and it isn't fazed by turbulence in Washington, CEO John Milligan said on Tuesday.

“A number of different opportunities … could play out over the coming year as we start to make progress in getting partnerships and potential acquisitions together,” Milligan said.

Where is the company looking? As he's said before, oncology is one major focus. And to help with that push, Gilead in January hired former Novartis exec Alessandro Riva, tasking the development veteran with rebuilding an outfit that has been damaged by a series of clinical setbacks and an executive departure last year.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

RELATED: Biopharma's Q1 earnings, all in one place

Questioned on whether political uncertainties in Washington are affecting Gilead’s search, Milligan said that Beltway indecision “seems to be the norm” during his 27 years at the drugmaker, and that the Gilead team isn’t rattled by ongoing political chatter.

“We're going to just focus on what's right for Gilead, try to ignore the noise globally on terms of tax reform,” Milligan said.

Analysts and investors are certainly ready for the company to make some moves. Quarter after quarter, they’ve pressed Gilead management for answers as the Big Biotech’s hepatitis C sales have taken a dive thanks to new competition from AbbVie and Merck.

RELATED: Making (good) deals is hard to do, Gilead CEO says, but he's working on it

That trend continued in the first quarter, when Gilead’s HCV sales crashed to $2.6 billion, down 50% from $4.6 billion during the same period last year. The company reported $6.5 billion in overall revenue, a 16% drop from last year’s first-quarter haul of $7.8 billion.

With that, Gilead execs faced familiar business development questions; early in the Q&A session, Barclays analyst Geoffrey Meacham asked about potential deal metrics. Milligan said Gilead is looking at margins, cash flows and options “that have a scientific and medical need such that we can build a sustainable business that would have the top line growth that we desire.”

RELATED: With hep C sales crashing, Gilead CEO Milligan concedes M&A is vital for growth

Following the company’s Q1 call and pipeline update, Barclays analysts said in an investor note that they “continue to favor growth via an external asset to offset” hepatitis C pressures. It remains to be seen exactly where the company will look to address those issues.

Gilead last year acquired a subsidiary of Nimbus Therapeutics in a deal worth up to $1.2 billion for a non-alcoholic liver disease drug now in phase 2.

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.